In cancer, antibodies that block PD-1/PD-L1 pathway could upsurge anti-tumor immunity via acting as a possible tumor suppressor therefore, regulating the reaction to anti-PD-1/PD-L1 treatments. This evidence concerns the gene CD274 and neoplasm.